New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
07:48 EDTLCILannett price target raised to $9 from $6 at Oppenheimer
Oppenheimer increased its price target on Lannett after the company reported higher than expected Q2 EPS. The firm notes that the company may be first-to-file for approval of thalidomide, now believed to represent a generic opportunity of 200M, and it maintains an Outperform rating on the shares.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2014
06:47 EDTLCILawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use